A novel classification method for LUAD that guides personalized immunotherapy on the basis of the cross-talk of coagulation- and macrophage-related genes

PurposeThe coagulation process and infiltration of macrophages affect the progression and prognosis of lung adenocarcinoma (LUAD) patients. This study was designed to explore novel classification methods that better guide the precise treatment of LUAD patients on the basis of coagulation and macroph...

Full description

Saved in:
Bibliographic Details
Main Authors: Zhuoqi Li, Ling Chen, Zhigang Wei, Hongtao Liu, Lu Zhang, Fujing Huang, Xiao Wen, Yuan Tian
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-02-01
Series:Frontiers in Immunology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2025.1518102/full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850195829704359936
author Zhuoqi Li
Ling Chen
Zhigang Wei
Hongtao Liu
Lu Zhang
Fujing Huang
Xiao Wen
Yuan Tian
author_facet Zhuoqi Li
Ling Chen
Zhigang Wei
Hongtao Liu
Lu Zhang
Fujing Huang
Xiao Wen
Yuan Tian
author_sort Zhuoqi Li
collection DOAJ
description PurposeThe coagulation process and infiltration of macrophages affect the progression and prognosis of lung adenocarcinoma (LUAD) patients. This study was designed to explore novel classification methods that better guide the precise treatment of LUAD patients on the basis of coagulation and macrophages.MethodsWeighted gene coexpression network analysis (WGCNA) was applied to identify M2 macrophage-related genes, and TAM marker genes were acquired through the analysis of scRNA-seq data. The MSigDB and KEGG databases were used to obtain coagulation-associated genes. The intersecting genes were defined as coagulation and macrophage-related (COMAR) genes. Unsupervised clustering analysis was used to evaluate distinct COMAR patterns for LUAD patients on the basis of the COMAR genes. The R package “limma” was used to identify differentially expressed genes (DEGs) between COMAR patterns. A prognostic risk score model, which was validated through external data cohorts and clinical samples, was constructed on the basis of the COMAR DEGs.ResultsIn total, 33 COMAR genes were obtained, and three COMAR LUAD subtypes were identified on the basis of the 33 COMAR genes. There were 341 DEGs identified between the three COMAR subtypes, and 60 prognostic genes were selected for constructing the COMAR risk score model. Finally, 15 prognosis-associated genes (CORO1A, EPHA4, FOXM1, HLF, IFIH1, KYNU, LY6D, MUC16, PPARG, S100A8, SPINK1, SPINK5, SPP1, VSIG4, and XIST) were included in the model, which was efficient and robust in predicting LUAD patient prognosis and clinical outcomes in patients receiving anti-PD-1/PD-L1 immunotherapy.ConclusionsLUAD can be classified into three subtypes according to COMAR genes, which may provide guidance for precise treatment.
format Article
id doaj-art-215e0fcd22cd42dbaa3d155dca71aeee
institution OA Journals
issn 1664-3224
language English
publishDate 2025-02-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Immunology
spelling doaj-art-215e0fcd22cd42dbaa3d155dca71aeee2025-08-20T02:13:39ZengFrontiers Media S.A.Frontiers in Immunology1664-32242025-02-011610.3389/fimmu.2025.15181021518102A novel classification method for LUAD that guides personalized immunotherapy on the basis of the cross-talk of coagulation- and macrophage-related genesZhuoqi Li0Ling Chen1Zhigang Wei2Hongtao Liu3Lu Zhang4Fujing Huang5Xiao Wen6Yuan Tian7Department of Radiotherapy Oncology, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, ChinaDepartment of Oncology, Qingdao Municipal Hospital, Qingdao, ChinaDepartment of Oncology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Shandong Lung Cancer Institute, Jinan, ChinaDepartment of Pathology, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Shandong Medicine and Health Key Laboratory of Clinical Pathology, Shandong Lung Cancer Institute, Shandong Institute of Nephrology, Jinan, ChinaDepartment of Radiotherapy Oncology, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, ChinaDepartment of Radiotherapy Oncology, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, ChinaDepartment of Radiotherapy Oncology, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, ChinaDepartment of Radiotherapy Oncology, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, ChinaPurposeThe coagulation process and infiltration of macrophages affect the progression and prognosis of lung adenocarcinoma (LUAD) patients. This study was designed to explore novel classification methods that better guide the precise treatment of LUAD patients on the basis of coagulation and macrophages.MethodsWeighted gene coexpression network analysis (WGCNA) was applied to identify M2 macrophage-related genes, and TAM marker genes were acquired through the analysis of scRNA-seq data. The MSigDB and KEGG databases were used to obtain coagulation-associated genes. The intersecting genes were defined as coagulation and macrophage-related (COMAR) genes. Unsupervised clustering analysis was used to evaluate distinct COMAR patterns for LUAD patients on the basis of the COMAR genes. The R package “limma” was used to identify differentially expressed genes (DEGs) between COMAR patterns. A prognostic risk score model, which was validated through external data cohorts and clinical samples, was constructed on the basis of the COMAR DEGs.ResultsIn total, 33 COMAR genes were obtained, and three COMAR LUAD subtypes were identified on the basis of the 33 COMAR genes. There were 341 DEGs identified between the three COMAR subtypes, and 60 prognostic genes were selected for constructing the COMAR risk score model. Finally, 15 prognosis-associated genes (CORO1A, EPHA4, FOXM1, HLF, IFIH1, KYNU, LY6D, MUC16, PPARG, S100A8, SPINK1, SPINK5, SPP1, VSIG4, and XIST) were included in the model, which was efficient and robust in predicting LUAD patient prognosis and clinical outcomes in patients receiving anti-PD-1/PD-L1 immunotherapy.ConclusionsLUAD can be classified into three subtypes according to COMAR genes, which may provide guidance for precise treatment.https://www.frontiersin.org/articles/10.3389/fimmu.2025.1518102/fullcoagulationmacrophageprognosisLUADclassification methodsrisk score model
spellingShingle Zhuoqi Li
Ling Chen
Zhigang Wei
Hongtao Liu
Lu Zhang
Fujing Huang
Xiao Wen
Yuan Tian
A novel classification method for LUAD that guides personalized immunotherapy on the basis of the cross-talk of coagulation- and macrophage-related genes
Frontiers in Immunology
coagulation
macrophage
prognosis
LUAD
classification methods
risk score model
title A novel classification method for LUAD that guides personalized immunotherapy on the basis of the cross-talk of coagulation- and macrophage-related genes
title_full A novel classification method for LUAD that guides personalized immunotherapy on the basis of the cross-talk of coagulation- and macrophage-related genes
title_fullStr A novel classification method for LUAD that guides personalized immunotherapy on the basis of the cross-talk of coagulation- and macrophage-related genes
title_full_unstemmed A novel classification method for LUAD that guides personalized immunotherapy on the basis of the cross-talk of coagulation- and macrophage-related genes
title_short A novel classification method for LUAD that guides personalized immunotherapy on the basis of the cross-talk of coagulation- and macrophage-related genes
title_sort novel classification method for luad that guides personalized immunotherapy on the basis of the cross talk of coagulation and macrophage related genes
topic coagulation
macrophage
prognosis
LUAD
classification methods
risk score model
url https://www.frontiersin.org/articles/10.3389/fimmu.2025.1518102/full
work_keys_str_mv AT zhuoqili anovelclassificationmethodforluadthatguidespersonalizedimmunotherapyonthebasisofthecrosstalkofcoagulationandmacrophagerelatedgenes
AT lingchen anovelclassificationmethodforluadthatguidespersonalizedimmunotherapyonthebasisofthecrosstalkofcoagulationandmacrophagerelatedgenes
AT zhigangwei anovelclassificationmethodforluadthatguidespersonalizedimmunotherapyonthebasisofthecrosstalkofcoagulationandmacrophagerelatedgenes
AT hongtaoliu anovelclassificationmethodforluadthatguidespersonalizedimmunotherapyonthebasisofthecrosstalkofcoagulationandmacrophagerelatedgenes
AT luzhang anovelclassificationmethodforluadthatguidespersonalizedimmunotherapyonthebasisofthecrosstalkofcoagulationandmacrophagerelatedgenes
AT fujinghuang anovelclassificationmethodforluadthatguidespersonalizedimmunotherapyonthebasisofthecrosstalkofcoagulationandmacrophagerelatedgenes
AT xiaowen anovelclassificationmethodforluadthatguidespersonalizedimmunotherapyonthebasisofthecrosstalkofcoagulationandmacrophagerelatedgenes
AT yuantian anovelclassificationmethodforluadthatguidespersonalizedimmunotherapyonthebasisofthecrosstalkofcoagulationandmacrophagerelatedgenes
AT zhuoqili novelclassificationmethodforluadthatguidespersonalizedimmunotherapyonthebasisofthecrosstalkofcoagulationandmacrophagerelatedgenes
AT lingchen novelclassificationmethodforluadthatguidespersonalizedimmunotherapyonthebasisofthecrosstalkofcoagulationandmacrophagerelatedgenes
AT zhigangwei novelclassificationmethodforluadthatguidespersonalizedimmunotherapyonthebasisofthecrosstalkofcoagulationandmacrophagerelatedgenes
AT hongtaoliu novelclassificationmethodforluadthatguidespersonalizedimmunotherapyonthebasisofthecrosstalkofcoagulationandmacrophagerelatedgenes
AT luzhang novelclassificationmethodforluadthatguidespersonalizedimmunotherapyonthebasisofthecrosstalkofcoagulationandmacrophagerelatedgenes
AT fujinghuang novelclassificationmethodforluadthatguidespersonalizedimmunotherapyonthebasisofthecrosstalkofcoagulationandmacrophagerelatedgenes
AT xiaowen novelclassificationmethodforluadthatguidespersonalizedimmunotherapyonthebasisofthecrosstalkofcoagulationandmacrophagerelatedgenes
AT yuantian novelclassificationmethodforluadthatguidespersonalizedimmunotherapyonthebasisofthecrosstalkofcoagulationandmacrophagerelatedgenes